Several other analysts also recently issued reports on the company. BidaskClub upgraded Quotient from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Zacks Investment Research upgraded Quotient from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th.
QTNT traded up $0.38 during trading on Thursday, hitting $11.26. The stock had a trading volume of 457,152 shares, compared to its average volume of 261,154. The stock has a 50 day simple moving average of $9.82. The company has a market capitalization of $699.39 million, a price-to-earnings ratio of -5.86 and a beta of 0.91. Quotient has a one year low of $5.52 and a one year high of $11.30. The company has a current ratio of 4.59, a quick ratio of 3.98 and a debt-to-equity ratio of 72.27.
In other news, President Edward Farrell sold 22,500 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $8.67, for a total transaction of $195,075.00. Following the completion of the sale, the president now directly owns 2,133 shares in the company, valued at approximately $18,493.11. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Frederick Hallsworth bought 3,150 shares of the business’s stock in a transaction dated Thursday, June 13th. The shares were bought at an average price of $8.70 per share, with a total value of $27,405.00. Following the completion of the transaction, the director now owns 74,398 shares in the company, valued at approximately $647,262.60. The disclosure for this purchase can be found here. Corporate insiders own 17.40% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Clearbridge Investments LLC lifted its position in shares of Quotient by 2.8% during the 1st quarter. Clearbridge Investments LLC now owns 2,456,616 shares of the company’s stock valued at $22,134,000 after acquiring an additional 67,290 shares during the period. PNC Financial Services Group Inc. bought a new stake in shares of Quotient during the 1st quarter valued at $1,854,000. Niemann Capital Management Inc. bought a new stake in shares of Quotient during the 1st quarter valued at $101,000. Artisan Partners Limited Partnership bought a new stake in shares of Quotient during the 1st quarter valued at $3,342,000. Finally, Knott David M lifted its position in shares of Quotient by 1.8% during the 1st quarter. Knott David M now owns 170,000 shares of the company’s stock valued at $1,532,000 after acquiring an additional 3,000 shares during the period. Hedge funds and other institutional investors own 63.94% of the company’s stock.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Article: Using other technical indicators with support levels
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.